Table 1 Patient characteristics
|  | FDG study (N = 22) | FLT study (N = 27) |
|---|---|---|
Mean (range) | Mean (range) | |
Age at registration, years | 62.0 (51–80) | 58.7 (28–74) |
Days between scans | 19.5 (7–40) | 27.2 (6–64) |
Days between 1st scan and surgery (AI therapy duration) | 22.5 (9–42) | 31.6 (9–69) |
Days between 2nd scan and surgery | 3.0 (1–6) | 4.3 (1–12)* |
| Â | N (%) | N (%) |
Female sex | 22 (100%) | 27 (100%) |
Race | ||
 Caucasian/White | 19 (86%) | 22 (82%) |
 Black/African American | – | 2 (7%) |
 Asian | 1 (5%) | 3 (11%) |
 Pacific Islander | 2 (9%) | – |
Ethnicity | ||
 Not hispanic or latino | 21 (95%) | 26 (96%) |
 Hispanic or latino | 1 (5%) | 1 (4%) |
Menopausal status | ||
 Postmenopausal | 22 (100%) | 20 (74%) |
 Premenopausal | – | 7 (26%) |
Aromatase inhibitor | ||
 Anastrozole | 18 (82%) | 22 (81%) |
 Letrozole | 4 (18%) | 5 (19%) |